Timser
TIMSER S.A.P.I. de C.V. is a biomedical company in Mexico developing accessible and non-invasive blood-based screening solutions for early detection of cervical cancer and its precursor lesions. The company leverages more than a decade of research to advance clinically validated molecular diagnostics using protein biomarkers identified through proteomics and molecular biology approaches. These technologies address barriers to traditional screening and are backed by extensive national and international patent coverage and clinical trial validation involving hundreds of participants.
Industries
Nr. of Employees
small (1-50)
Timser
Avenida Adolfo López Mateos, Periférico Sur 4349, Local 6, Jardines en la Montaña, Tlalpan, 14210, Ciudad de México, Mexico
Products
Blood-based molecular screening test for cervical cancer
A clinically validated diagnostic platform detecting a panel of circulating protein biomarkers from blood samples to identify risk of cervical precancerous lesions and cancer as an accessible, non-invasive alternative to cytology and HPV-based tests.
Blood-based molecular screening test for cervical cancer
A clinically validated diagnostic platform detecting a panel of circulating protein biomarkers from blood samples to identify risk of cervical precancerous lesions and cancer as an accessible, non-invasive alternative to cytology and HPV-based tests.
Expertise Areas
- Cervical cancer biomarker screening
- Molecular diagnostics
- Female health technology (FemTech)
- Clinical protocol development and validation
Key Technologies
- Multiplex immunodetection (lateral flow, ELISA)
- Mass spectrometry (LC-MS/MS, MALDI-TOF)
- 2D gel electrophoresis
- Surface plasmon resonance
News & Updates
Awarded 'Iconic Company Creating a Better World for All' for contributions to women's health innovation.
Showcased molecular diagnostic advancements in one of the leading forums for female leadership.
Highlighted as an example of biotechnological and social innovation in women’s health.
Presented clinical findings of its screening technology at a major regional medical congress.
Recognized as one of the most promising FemTech startups internationally.
Secured investment from Impact Ventures aimed at expanding preventive screening efforts.
Awarded 'Iconic Company Creating a Better World for All' for contributions to women's health innovation.
Showcased molecular diagnostic advancements in one of the leading forums for female leadership.
Highlighted as an example of biotechnological and social innovation in women’s health.
Presented clinical findings of its screening technology at a major regional medical congress.
Recognized as one of the most promising FemTech startups internationally.
Secured investment from Impact Ventures aimed at expanding preventive screening efforts.